TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 36291912

Group type: EXPERIMENTAL
Intervention: MEMMAT-like metronomic antiangiogenic approach including daily oral thalidomide, fenofibrate, celecoxib, alternating 21-day cycles of low-dose oral etoposide and cyclophosphamide, IV bevacizumab, and intraventricular therapy with alternating etoposide and liposomal cytarabine.
Number of subjects: 29
Study: 36293719

Group type: EXPERIMENTAL
Intervention: Asymptomatic SARS-CoV-2 testing service (ATS)
Number of subjects: 25
Study: 36294501

Group type: EXPERIMENTAL
Intervention: SF-36 PCS ≤ 50
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: mEHRA score
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: SF-36 MCS ≤ 50
Number of subjects: 158
Study: 36294516

Group type: EXPERIMENTAL
Intervention: Invasive endovascular treatment for CVS
Number of subjects: 34

Group type: COMPARATOR
Intervention: Conservative therapy
Number of subjects: 34
Study: 36295001

Group type: EXPERIMENTAL
Intervention: COVID-19 convalescent plasma (CCP) transfusion (single unit with anti-RBD IgG concentration > 5 AU/mL)
Number of subjects: 189
Study: 36295843

Group type: EXPERIMENTAL
Intervention: Untargeted SWATH metabolomics
Number of subjects: 886

Group type: EXPERIMENTAL
Intervention: Integration with pharmacogenomics data
Number of subjects: 886
Study: 36296957

Group type: EXPERIMENTAL
Intervention: Intuitive Eating (IE) assessed using EPR and RHSC subscales
Number of subjects: 179

Group type: EXPERIMENTAL
Intervention: Diet quality assessed using the Alternative Health Eating Index (AHEI)
Number of subjects: 179
Study: 36297443

Group type: EXPERIMENTAL
Intervention: DUO scheme (three cycles of [177Lu]Lu-DOTATOC alternated with two cycles of [90Y]Y-DOTATOC)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: MONO scheme (five cycles of [177Lu]Lu-DOTATOC)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Both DUO and MONO schemes
Number of subjects: 56
Study: 36298700

Group type: EXPERIMENTAL
Intervention: cCMV infection
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: EV-associated IP-10
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Severity of fetal infection
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Specific increase in six proteins
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Fetal infection and its severity
Number of subjects: 80
Study: 36299240

Group type: EXPERIMENTAL
Intervention: Zinc-finger nuclease (ZFN) therapy at 1e13 vg/kg dose
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Zinc-finger nuclease (ZFN) therapy at 5e13 vg/kg dose
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Zinc-finger nuclease (ZFN) therapy for hemophilia B
Number of subjects: 13
Study: 36299500

Group type: EXPERIMENTAL
Intervention: GAA enzyme assay
Number of subjects: 921
Study: 36300324

Group type: EXPERIMENTAL
Intervention: Psychoeducational, guided mHealth intervention to prevent postpartum mental health difficulties
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 36300352

Group type: EXPERIMENTAL
Intervention: Early Recovery (answered yes to PASS at 1 and 6-months)
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Delayed Recovery (PASS-yes only at 6-months)
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Unrecovered
Number of subjects: 140

Group type: COMPARATOR
Intervention: Early Recovery
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: SPADI change scores
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: QDASH change scores
Number of subjects: 140
Study: 36300662

Group type: EXPERIMENTAL
Intervention: Lower-body negative pressure (LBNP) at -30 mmHg
Number of subjects: 1

Group type: COMPARATOR
Intervention: Supine rest (baseline)
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: Lower-body negative pressure (LBNP)
Number of subjects: 1
Study: 36301137

Group type: EXPERIMENTAL
Intervention: Pembrolizumab (PD-1 inhibitor)
Number of subjects: 24
Study: 36301338

Group type: EXPERIMENTAL
Intervention: Daratumumab 16 mg/kg
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Daratumumab 8 mg/kg
Number of subjects: 50
Study: 36301572

Group type: EXPERIMENTAL
Intervention: Olaparib (200 mg twice daily)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Olaparib with radiotherapy
Number of subjects: 24
Study: 36301599

Group type: EXPERIMENTAL
Intervention: Mobile app with usual care
Number of subjects: 40

Group type: COMPARATOR
Intervention: Usual care alone
Number of subjects: 40
Study: 36301604

Group type: EXPERIMENTAL
Intervention: Mindfulness training via a smartphone app (10 weekly sessions, daily practice)
Number of subjects: 0
Study: 36301615

Group type: EXPERIMENTAL
Intervention: App-based Cognition Kit Digit Symbol Substitution Test (DSST)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Standard paper-and-pencil version of the DSST
Number of subjects: 30
Study: 36301921

Group type: EXPERIMENTAL
Intervention: Circulating biomarkers assessment (38 biomarkers: 27 proteins, 11 mRNAs) at sepsis diagnosis
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: Hierarchical clustering and k-means algorithm for patient grouping
Number of subjects: 203
Study: 36301928

Group type: EXPERIMENTAL
Intervention: Dissolved tablet of EVG/COBI/FTC/TAF
Number of subjects: 12

Group type: COMPARATOR
Intervention: Whole tablet of EVG/COBI/FTC/TAF
Number of subjects: 12
Study: 36302159

Group type: EXPERIMENTAL
Intervention: Immediate insertion of contraceptive implants
Number of subjects: 2609

Group type: EXPERIMENTAL
Intervention: Immediate insertion of IUDs
Number of subjects: 2609

Group type: COMPARATOR
Intervention: Delayed insertion of contraceptive implants
Number of subjects: 2609

Group type: COMPARATOR
Intervention: Delayed insertion of IUDs
Number of subjects: 2609

Group type: EXPERIMENTAL
Intervention: Immediate insertion of progestin-releasing implants and IUDs
Number of subjects: 2609
Study: 36302167

Group type: EXPERIMENTAL
Intervention: Cold atmospheric pressure plasma
Number of subjects: 0
Study: 36302175

Group type: EXPERIMENTAL
Intervention: Guadecitabine (subcutaneously, 45 mg/m2/day for 5 consecutive days, planned 28-day cycle)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Guadecitabine
Number of subjects: 9
Study: 36302562

Group type: EXPERIMENTAL
Intervention: Ivuxolimab (0.1-3 mg/kg every 2 weeks) + utomilumab (20 or 100 mg every 4 weeks)
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Ivuxolimab (30 mg every 2 weeks) + utomilumab (20 mg every 4 weeks)
Number of subjects: 87
Study: 36302579

Group type: EXPERIMENTAL
Intervention: Moderate-to-vigorous physical activity (MVPA) in 2020
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: MVPA during school hours in 2020
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: MVPA during out-of-school time on weekdays in 2020
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: MVPA during weekends in 2020
Number of subjects: 174

Group type: COMPARATOR
Intervention: Participation in youth sports in 2020
Number of subjects: 174

Group type: COMPARATOR
Intervention: Participation in youth clubs in 2020
Number of subjects: 174

Group type: COMPARATOR
Intervention: Participation in other out-of-school activities in 2020
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: Weekly physical education (PE) and recess minutes in 2020
Number of subjects: 174
Study: 36302584

Group type: EXPERIMENTAL
Intervention: Canagliflozin
Number of subjects: 14543

Group type: COMPARATOR
Intervention: Baseline eGFR <45 mL/min/1.73 m²
Number of subjects: 14543

Group type: COMPARATOR
Intervention: Baseline eGFR 45-60 mL/min/1.73 m²
Number of subjects: 14543

Group type: COMPARATOR
Intervention: Baseline eGFR >60 mL/min/1.73 m²
Number of subjects: 14543
Study: 36302586

Group type: EXPERIMENTAL
Intervention: Biomarker-based prediction model (ABC-ACS ischemia score)
Number of subjects: 10713

Group type: EXPERIMENTAL
Intervention: Growth differentiation factor 15 and N-terminal pro-B-type natriuretic peptide biomarkers
Number of subjects: 10713

Group type: EXPERIMENTAL
Intervention: Cox regression models
Number of subjects: 10713
Study: 36303108

Group type: EXPERIMENTAL
Intervention: Regional citrate anticoagulation with continuous infusion of 8% trisodium citrate into the arterial line and supplementation of 1 M calcium chloride into the venous line
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Regional citrate anticoagulation
Number of subjects: 5
Study: 36303136

Group type: EXPERIMENTAL
Intervention: Cemented TKA
Number of subjects: 5961

Group type: COMPARATOR
Intervention: Cementless TKA
Number of subjects: 5961
Study: 36303228

Group type: EXPERIMENTAL
Intervention: Pembrolizumab (200 mg IV on day 8 of a 21-day cycle), low-dose cyclophosphamide (50 mg orally twice daily for 1 week on and 1 week off), and G100 (20 µg intra-tumoral injection weekly for at least 6 weeks, maximum 12 weeks)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: G100 (20 µg intra-tumoral injection weekly)
Number of subjects: 20
Study: 36303332

Group type: EXPERIMENTAL
Intervention: Internet-delivered cognitive behavioural therapy program
Number of subjects: 16
Study: 36303402

Group type: EXPERIMENTAL
Intervention: Ventricular fibrillation (VF) group
Number of subjects: 14423

Group type: COMPARATOR
Intervention: Non-VF group
Number of subjects: 14423
Study: 36303432

Group type: EXPERIMENTAL
Intervention: Culture-positive relapse
Number of subjects: 724

Group type: EXPERIMENTAL
Intervention: CSF WBC <5 cells/μL
Number of subjects: 724

Group type: EXPERIMENTAL
Intervention: CD4 counts <50 cells/μL
Number of subjects: 724

Group type: COMPARATOR
Intervention: First episodes of cryptococcal meningitis
Number of subjects: 724

Group type: COMPARATOR
Intervention: Culture-positive relapses
Number of subjects: 724

Group type: COMPARATOR
Intervention: Paradoxical IRIS
Number of subjects: 724
Study: 36303445

Group type: EXPERIMENTAL
Intervention: eSCCIP (Electronic Surviving Cancer Competently Intervention Program)
Number of subjects: 44
Study: 36303658

Group type: EXPERIMENTAL
Intervention: Remotely delivered, group-based lifestyle intervention
Number of subjects: 12
Study: 36303659

Group type: EXPERIMENTAL
Intervention: Contraceptive vaginal ring (CCVR)
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Net-En (injectable norethisterone-enanthate)
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Combined oral contraceptives (COC)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Control group (other contraceptive groups)
Number of subjects: 130
Study: 36304034

Group type: EXPERIMENTAL
Intervention: Intervention by and for transgender women living with HIV
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 36304240

Group type: EXPERIMENTAL
Intervention: Preventive measures (e.g., social distancing, mask usage)
Number of subjects: 4004
Study: 36304457

Group type: EXPERIMENTAL
Intervention: Pembrolizumab 2 mg/kg every 3 weeks for ≤35 cycles
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Number of subjects: 0
Study: 36305298

Group type: EXPERIMENTAL
Intervention: Temporary mechanical circulatory supports and aggressive immunosuppression
Number of subjects: 0
Study: 36305577

Group type: EXPERIMENTAL
Intervention: Clinical and polysomnography (PSG)/multiple sleep latency test (MSLT) results
Number of subjects: 89

Group type: COMPARATOR
Intervention: Comparison with European Narcolepsy Network (EU-NN) data
Number of subjects: 89
Study: 36305957

Group type: EXPERIMENTAL
Intervention: Ipatasertib 400 mg once-daily orally
Number of subjects: 1101
Study: 36306154

Group type: EXPERIMENTAL
Intervention: Movement-to-Music (M2M) program with behavioral telecoaching, 4-week duration, videos completed 3 times each week at home.
Number of subjects: 58

Group type: COMPARATOR
Intervention: Waitlist control group maintaining daily activities.
Number of subjects: 58
Study: 36306161

Group type: EXPERIMENTAL
Intervention: CARE intervention (social media-based diabetes self-management videos delivered via WeChat, biweekly phone calls from community health workers)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 60
Study: 36306158

Group type: EXPERIMENTAL
Intervention: Training Intervention and Program of Support (TIPS) consisting of a 1-month training intervention with self-paced learning modules and a webinar, followed by an 11-month support program including monthly site meetings and access to a virtual community of practice.
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: TIPS implementation assessed through an interrupted time series design.
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Qualitative data collection during implementation analyzed using a deductive-inductive thematic approach.
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Quasi-experimental pretest-posttest design using questionnaires.
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Manager, therapist, and family interviews conducted after implementation.
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Cost data gathered to calculate public system and societal costs.
Number of subjects: 20
Study: 36306162

Group type: EXPERIMENTAL
Intervention: Booster emails containing personalized feedback
Number of subjects: 18

Group type: COMPARATOR
Intervention: No booster emails (control group)
Number of subjects: 18
Study: 36306335

Group type: EXPERIMENTAL
Intervention: Left Bundle Branch Pacing (LBBP)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Biventricular Pacing (BVP)
Number of subjects: 21
Study: 36306341

Group type: EXPERIMENTAL
Intervention: Gated cardiac computed tomography (CT)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Lower fibrosis scores (1+2)
Number of subjects: 200
Study: 36306387

Group type: EXPERIMENTAL
Intervention: In utero transfusions (IUTs)
Number of subjects: 60
Study: 36306481

Group type: EXPERIMENTAL
Intervention: G8 Geriatric Screening Tool
Number of subjects: 1648

Group type: EXPERIMENTAL
Intervention: Modified G8 score
Number of subjects: 1648

Group type: EXPERIMENTAL
Intervention: Geriatric Assessment (GA)
Number of subjects: 1648
Study: 36306483

Group type: EXPERIMENTAL
Intervention: Early Treatment Discontinuation (ETD)
Number of subjects: 10447

Group type: EXPERIMENTAL
Intervention: Early Oxaliplatin Discontinuation (EOD)
Number of subjects: 10447

Group type: COMPARATOR
Intervention: 6 months of oxaliplatin-based chemotherapy
Number of subjects: 10447
Study: 36306520

Group type: EXPERIMENTAL
Intervention: PrEP Difficulties Scale
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PrEP Confidence Scale
Number of subjects: 0
Study: 36306532

Group type: EXPERIMENTAL
Intervention: Patients with LADA
Number of subjects: 0

Group type: COMPARATOR
Intervention: Healthy controls (HCs)
Number of subjects: 0
Study: 36306569

Group type: EXPERIMENTAL
Intervention: Motor learning principles applied during physiotherapy sessions
Number of subjects: 57
Study: 36306803

Group type: EXPERIMENTAL
Intervention: Vedolizumab
Number of subjects: 142
Study: 36306810

Group type: EXPERIMENTAL
Intervention: Standard whole-breast radiotherapy (40 Gy in 15 fractions or 50 Gy in 25 fractions) plus a boost (14 Gy in seven fractions) after image-guided VACB-determined pathological complete response following NST.
Number of subjects: 50
Study: 36306921

Group type: EXPERIMENTAL
Intervention: Autologous tolerogenic dendritic cells (ATDC)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Standard immunosuppression with basiliximab
Number of subjects: 17
Study: 36307040

Group type: EXPERIMENTAL
Intervention: Durvalumab (10 mg/kg every 2 weeks)
Number of subjects: 1399
Study: 36307044

Group type: EXPERIMENTAL
Intervention: Targeted next-generation sequencing covering 42 aortic diseases genes
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Family screening
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Statistical analysis of demographic features, risk factors, and clinical symptoms
Number of subjects: 73
Study: 36307158

Group type: EXPERIMENTAL
Intervention: Qualitative exploration of character strengths among patients with breast cancer
Number of subjects: 24
Study: 36307159

Group type: EXPERIMENTAL
Intervention: Self-reported opioid consumption using a 14-day diary (paper or electronic)
Number of subjects: 166
Study: 36307164

Group type: EXPERIMENTAL
Intervention: Palliative Care Referral System (PCRS) implemented after development and testing.
Number of subjects: 300

Group type: COMPARATOR
Intervention: Standard care before implementation of PCRS.
Number of subjects: 300
Study: 36307178

Group type: EXPERIMENTAL
Intervention: High-risk adenomas
Number of subjects: 15581

Group type: EXPERIMENTAL
Intervention: Low-risk adenomas
Number of subjects: 15581

Group type: EXPERIMENTAL
Intervention: Overall population
Number of subjects: 15581

Group type: EXPERIMENTAL
Intervention: Second colonoscopy
Number of subjects: 15581
Study: 36307410

Group type: EXPERIMENTAL
Intervention: Ad-sig-hMUC1/ecdCD40L adenoviral-vector vaccine
Number of subjects: 21
Study: 36307462

Group type: EXPERIMENTAL
Intervention: Interferon-β1b and lopinavir-ritonavir
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study: 36307601

Group type: EXPERIMENTAL
Intervention: Peritoneal lavage (PL) used in laparoscopic appendectomy (LA)
Number of subjects: 561

Group type: EXPERIMENTAL
Intervention: Surgical evaluation of appendicitis severity
Number of subjects: 561

Group type: EXPERIMENTAL
Intervention: Subjective difficulty assessment using a five-point Likert scale
Number of subjects: 561

Group type: EXPERIMENTAL
Intervention: Intraoperative findings of gangrenous or perforated appendicitis
Number of subjects: 561
Study: 36307607

Group type: EXPERIMENTAL
Intervention: Femtosecond laser
Number of subjects: 100

Group type: COMPARATOR
Intervention: Microkeratome
Number of subjects: 100
Study: 36307738

Group type: EXPERIMENTAL
Intervention: PET/CT combined with clinical parameters
Number of subjects: 0
Study: 36307775

Group type: EXPERIMENTAL
Intervention: SCT200 (anti-EGFR monoclonal antibody) administered intravenously every 3 weeks at doses ranging from 0.5-15.0 mg/kg.
Number of subjects: 56
Study: 36307803

Group type: EXPERIMENTAL
Intervention: Individuals with RKOA
Number of subjects: 282

Group type: EXPERIMENTAL
Intervention: Individuals with RKOA (normal BMI subgroup, n=126)
Number of subjects: 282

Group type: EXPERIMENTAL
Intervention: Individuals with obesity
Number of subjects: 282

Group type: COMPARATOR
Intervention: Individuals without RKOA
Number of subjects: 282
Study: 36307826

Group type: EXPERIMENTAL
Intervention: Eribulin, administered for a median of 4.5 cycles (1-23 cycles), with a median overall survival of 12 months.
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Eribulin, with reported severe AEs including neutropenia (15.3%) and neurotoxicity (14.7%).
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Eribulin, with genetic polymorphisms analysis for 15 SNPs.
Number of subjects: 180
Study: 36307845

Group type: EXPERIMENTAL
Intervention: Intraoperative radiation therapy (IORT) 15 Gy/1 fraction after SBRT 40 Gy/5 fractions
Number of subjects: 0
Study: 36308640

Group type: EXPERIMENTAL
Intervention: Topical application of 100 mg CBD:100 mg THC
Number of subjects: 39
Study: 36309156

Group type: EXPERIMENTAL
Intervention: Rapid VT/VF group (28 patients with rapid VT/VF episodes)
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Rapid VT/VF group
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: VT/VF episodes
Number of subjects: 144

Group type: COMPARATOR
Intervention: First documented nonrapid VT episode
Number of subjects: 144
Study: 36309347

Group type: EXPERIMENTAL
Intervention: COVID-19 vaccination with reported adverse events
Number of subjects: 1430

Group type: EXPERIMENTAL
Intervention: COVID-19 vaccination with short-term VAEs
Number of subjects: 1430
Study: 36309488

Group type: EXPERIMENTAL
Intervention: High-intensity inspiratory muscle training (IMT) at home, 80% of max, daily in Phase 1 and 2, once weekly in Phase 3, self-selected frequency in Phase 4, with one weekly supervised session except Phase 4
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control group (not explicitly detailed in the abstract)
Number of subjects: 10
Study: 36309572

Group type: EXPERIMENTAL
Intervention: Intravitreal aflibercept (IVT-AFL) treatment
Number of subjects: 402
Study: 36309748

Group type: EXPERIMENTAL
Intervention: Very low-energy diet (VLED) for 12 months
Number of subjects: 246
Study: 36309837

Group type: EXPERIMENTAL
Intervention: Epacadostat (300 mg) plus durvalumab
Number of subjects: 0
Study: 36309981

Group type: EXPERIMENTAL
Intervention: Venetoclax (100, 200, or 400 mg daily for 14 days every 28-day cycle) + Azacitidine (75 mg/m² on Days 1-7 every cycle)
Number of subjects: 0
Study: 36310331

Group type: EXPERIMENTAL
Intervention: Cobimetinib
Number of subjects: 655
Study: 36310395

Group type: EXPERIMENTAL
Intervention: Qualitative interviews with unvaccinated ED patients regarding COVID-19 vaccination concerns and potential approaches to increase vaccine acceptance.
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Trusted messengers identified during interviews.
Number of subjects: 65
Study: 36310566

Group type: EXPERIMENTAL
Intervention: Proton pump inhibitor (PPI) with feeding modifications
Number of subjects: 94

Group type: COMPARATOR
Intervention: Proton pump inhibitor (PPI) alone
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: I-GERQ-R
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: PPI therapy
Number of subjects: 94
Study: 36311227

Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Resistance exercise
Number of subjects: 54

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 54
Study: 36311929

Group type: EXPERIMENTAL
Intervention: 3D reconstruction CT
Number of subjects: 190

Group type: COMPARATOR
Intervention: Standard chest CT
Number of subjects: 190
Study: 36313025

Group type: EXPERIMENTAL
Intervention: Facility-based multidomain intervention (FMI) for 24 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 36313054

Group type: EXPERIMENTAL
Intervention: Comprehensive geriatric assessment in the emergency department
Number of subjects: 0
Study: 36313083

Group type: EXPERIMENTAL
Intervention: Mediterranean Diet (MD) with standard obstetrical and gynecological follow-up and nutritional counseling to promote MD
Number of subjects: 138

Group type: COMPARATOR
Intervention: Standard obstetrical and gynecological follow-up alone
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: Mediterranean Diet (MD)
Number of subjects: 138
Study: 36313089

Group type: EXPERIMENTAL
Intervention: Breastfeeding (BF)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Experimental infant formula (EF)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Standard infant formula (SF)
Number of subjects: 62
Study: 36313095

Group type: EXPERIMENTAL
Intervention: High fibre/low red and processed meat intake (HFLM)
Number of subjects: 233

Group type: COMPARATOR
Intervention: Low fibre/high red and processed meat intake (LFHM)
Number of subjects: 233

Group type: EXPERIMENTAL
Intervention: High fibre/low red and processed meat intake (HFLM) in RA patients
Number of subjects: 233